nach oben

Drug Safety

Erschienen in:

01.01.2013 | Correspondence

Artesunate- and Amodiaquine-Associated Extrapyramidal Reactions

Information Gained from an African-Based Risk Management Plan

verfasst von: François Bompart

Erschienen in: Drug Safety | Ausgabe 1/2013

Einloggen, um Zugang zu erhalten

Excerpt

In an article recently published in Drug Safety [1], McEwen mentions that “… the Summary of Product Characteristics (SPC) for Artesunate Amodiaquine Winthrop^® refers to somnolence, paraesthesias, headache, dizziness, convulsion and rare neuromyopathy. There is no mention of movement disorders, extrapyramidal disorders or their common pathognomonic symptoms, which is curious as the SPC purports to include additional types of events that have been attributed to amodiaquine in the published literature”. I think it may be helpful to provide further information on this. …

McEwen J. Artesunate- and amodiaquine-associated extrapyramidal reactions: a series of 49 cases in VigiBase™. Drug Saf. 2012;35(8):667–75.PubMed

Titel: Artesunate- and Amodiaquine-Associated Extrapyramidal Reactions
Information Gained from an African-Based Risk Management Plan
verfasst von: François Bompart
Publikationsdatum: 01.01.2013
Verlag: Springer International Publishing AG
Erschienen in: Drug Safety / Ausgabe 1/2013
Print ISSN: 0114-5916
Elektronische ISSN: 1179-1942
DOI: https://doi.org/10.1007/s40264-012-0010-x

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2013

Pharmacovigilance in the Middle East

Maternal Recall of Prescription Medication Use During Pregnancy Using a Paper-Based Questionnaire

Key Elements in Adverse Drug Interaction Safety Signals

A Reference Standard for Evaluation of Methods for Drug Safety Signal Detection Using Electronic Healthcare Record Databases

Opportunities to Reduce Medication Regimen Complexity

Pharmacovigilance of Herbal Medicines